Epidermolysis Bullosa - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Epidermolysis Bullosa - Pipeline Review, H2 2018’, provides an overview of the Epidermolysis Bullosa pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa

- The report reviews pipeline therapeutics for Epidermolysis Bullosa by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Epidermolysis Bullosa therapeutics and enlists all their major and minor projects

- The report assesses Epidermolysis Bullosa therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abeona Therapeutics Inc

Almirall SA

Amryt Pharma plc

Anterogen Co Ltd

Berg LLC

Celularity Inc

CSL Ltd

Fibrocell Science Inc

GlaxoSmithKline Plc

Immusoft Corp

InMed ...

Abeona Therapeutics Inc

Almirall SA

Amryt Pharma plc

Anterogen Co Ltd

Berg LLC

Celularity Inc

CSL Ltd

Fibrocell Science Inc

GlaxoSmithKline Plc

Immusoft Corp

InMed Pharmaceuticals Inc

Krystal Biotech Inc

MallInckrodt Plc

Mesoblast Ltd

Palvella Therapeutics LLC

ProQR Therapeutics NV

RegeneRx Biopharmaceuticals Inc

Shionogi & Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Epidermolysis Bullosa - Overview

Epidermolysis Bullosa - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Epidermolysis Bullosa - Overview

Epidermolysis Bullosa - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Epidermolysis Bullosa - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Epidermolysis Bullosa - Companies Involved in Therapeutics Development

Abeona Therapeutics Inc

Almirall SA

Amryt Pharma plc

Anterogen Co Ltd

Berg LLC

Celularity Inc

CSL Ltd

Fibrocell Science Inc

GlaxoSmithKline Plc

Immusoft Corp

InMed Pharmaceuticals Inc

Krystal Biotech Inc

MallInckrodt Plc

Mesoblast Ltd

Palvella Therapeutics LLC

ProQR Therapeutics NV

RegeneRx Biopharmaceuticals Inc

Shionogi & Co Ltd

Epidermolysis Bullosa - Drug Profiles

AC-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADP-31415 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGLE-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZT-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

birch bark extract - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Dermatology and Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CL-2020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSL-730 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Dystrophic Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCX-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate COL7A1 for Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate COL7A1 for Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Lysyl Hydroxylase-3 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target COL7A1 for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOLOGENE-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICX-RHY - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INM-750 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISN-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PDA-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-313 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-323 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QRX-333 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target COL7A1 for Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remestemcel-L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGN-137 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-005151 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Diabetic Foot Ulcers, Epidermolysis Bullosa, Liver Diseases, Kidney Disease, Peripheral Artery Occlusive Disease and Skin Ulcers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-127 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ubidecarenone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Epidermolysis Bullosa - Dormant Projects

Epidermolysis Bullosa - Discontinued Products

Epidermolysis Bullosa - Product Development Milestones

Featured News & Press Releases

Sep 25, 2018: Fibrocell awarded $1.4 million FDA orphan grant for FCX-007 for treatment of recessive dystrophic epidermolysis bullosa

Sep 10, 2018: Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites

Aug 09, 2018: Castle Creek Pharmaceuticals receives FDA Fast Track Designation for Diacerein 1% ointment for treatment of Epidermolysis Bullosa Simplex

Aug 02, 2018: FDA grants Pediatric Rare Disease designation for AP101 for patients with Epidermolysis Bullosa

Jul 16, 2018: Krystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018

Jun 25, 2018: Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment

May 24, 2018: U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa

May 23, 2018: BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa

May 21, 2018: Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

May 17, 2018: Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting

May 17, 2018: Celularity and New York Medical College Partner on a Breakthrough Study to Treat RDEB with Human Placental Derived Stem Cells

May 16, 2018: Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa

May 16, 2018: Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting

May 10, 2018: Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa

May 09, 2018: Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Epidermolysis Bullosa, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Epidermolysis Bullosa, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, H2 2018

Epidermolysis Bullosa - Pipeline by Almirall SA, H2 2018

Epidermolysis Bullosa - Pipeline by Amryt Pharma plc, H2 2018

Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, H2 2018

Epidermolysis Bullosa - Pipeline by Berg LLC, H2 2018

Epidermolysis Bullosa - Pipeline by Celularity Inc, H2 2018

Epidermolysis Bullosa - Pipeline by CSL Ltd, H2 2018

Epidermolysis Bullosa - Pipeline by Fibrocell Science Inc, H2 2018

Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H2 2018

Epidermolysis Bullosa - Pipeline by Immusoft Corp, H2 2018

Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, H2 2018

Epidermolysis Bullosa - Pipeline by Krystal Biotech Inc, H2 2018

Epidermolysis Bullosa - Pipeline by MallInckrodt Plc, H2 2018

Epidermolysis Bullosa - Pipeline by Mesoblast Ltd, H2 2018

Epidermolysis Bullosa - Pipeline by Palvella Therapeutics LLC, H2 2018

Epidermolysis Bullosa - Pipeline by ProQR Therapeutics NV, H2 2018

Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2018

Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, H2 2018

Epidermolysis Bullosa - Dormant Projects, H2 2018

Epidermolysis Bullosa - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Epidermolysis Bullosa, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Epidermolysis Bullosa, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports